A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications
Public ClinicalTrials.gov record NCT02408523. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-blind, Randomized, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Lacosamide as Adjunctive Therapy for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects With Idiopathic Generalized Epilepsy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Evaluating efficacy \& safety of lacosamide versus Placebo in a blinded fashion as add-on Therapy for Primary Generalized Tonic-clonic (PGTC) seizures in subject 4 years of age or greater with idiopathic generalized epilepsy currently taking 1 to 3 antiepileptic drugs. Maximum duration of study drug administration is 28 weeks. Eligible subjects may choose to enter the open-label extension study after completion.
Study identification
- NCT ID
- NCT02408523
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 242 participants
Conditions and interventions
Conditions
Interventions
- Lacosamide Tablet Drug
- Lasosamide Oral Solution Drug
- Placebo Tablet Other
- Placebo Oral Solution Other
Drug · Other
Eligibility (public fields only)
- Age range
- 4 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2015 (Actual)
- Primary completion
- Apr 2019 (Actual)
- Completion
- Jun 2019 (Actual)
- Last update posted
- Dec 17, 2020
2015 – 2019
United States locations
- U.S. sites
- 27
- U.S. states
- 16
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sp0982 028 | Alabaster | Alabama | 35007 | — |
| Sp0982 005 | Little Rock | Arkansas | 72205 | — |
| Sp0982 018 | Irvine | California | 92868 | — |
| Sp0982 008 | Santa Monica | California | 90404 | — |
| Sp0982 031 | Colorado Springs | Colorado | 80910 | — |
| Sp0982 035 | Denver | Colorado | 80202 | — |
| Sp0982 036 | Danbury | Connecticut | 06810 | — |
| Sp0982 011 | Jacksonville | Florida | 32224 | — |
| Sp0982 013 | Panama City | Florida | 32405 | — |
| Sp0982 002 | Port Charlotte | Florida | 33952 | — |
| Sp0982 042 | Wellington | Florida | 33470 | — |
| Sp0982 015 | Boise | Idaho | 83702 | — |
| Sp0982 021 | Peoria | Illinois | 61637 | — |
| Sp0982 045 | Springfield | Illinois | 62702 | — |
| Sp0982 009 | New Orleans | Louisiana | 70121 | — |
| Sp0982 007 | Bethesda | Maryland | 20817 | — |
| Sp0982 010 | Waldorf | Maryland | 20603 | — |
| Sp0982 025 | Golden Valley | Minnesota | 55422 | — |
| Sp0982 029 | St Louis | Missouri | 63131 | — |
| Sp0982 043 | New York | New York | 10016 | — |
| Sp0982 053 | Austin | Texas | 78758 | — |
| Sp0982 050 | Greenville | Texas | 75401 | — |
| Sp0982 034 | Houston | Texas | 77025 | — |
| Sp0982 047 | San Antonio | Texas | 78207 | — |
| Sp0982 038 | San Antonio | Texas | 78229 | — |
| Sp0982 027 | Renton | Washington | 98057 | — |
| Sp0982 023 | Madison | Wisconsin | 53715 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 88 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02408523, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 17, 2020 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02408523 live on ClinicalTrials.gov.